A Phase 3 Randomized, Double-blinded, Active-controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Fabagal® (Agalsidase Beta) in Patients With Fabry Disease
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 24
- 试验地点
- 3
- 主要终点
- Evaluate the efficacy of Fabagal compared with active comparator (Agalsidase beta)
研究概览
简要总结
Evaluate the safety and efficacy of Fabagal® developed by ISU ABXIS Co., Ltd., which has similar efficacy to active comparator (Agalsidase beta).
详细描述
The primary objective is to evaluate the efficacy of Fabagal compared to active comparator (Agalsidase beta). The secondary objectives will evaluate the safety, pharmacokinetics, and immunogenicity of Fabagal compared to active comparator (Agalsidase beta).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 8 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Those who have been diagnosed with Fabry disease by genetic and alpha-galactosidase A enzyme tests and grouped by sex are as follows:
- •Male: Those who have confirmed GLA mutation (variation of α-galactosidase A gene) by genetic testing, and whose activity of alpha-galactosidase A in leukocytes is 5% or less than the normal mean value
- •Female: Those who have confirmed GLA mutation by genetic testing, and whose alpha-galactosidase A is within the normal range or is deficient
- •Age: Those who are aged 8 years or older
- •Those who have at least one of the following symptoms and signs:
- •Glomerular filtration rate decreased (Inclusion criteria: 2 or more cases of 30 ≦ eGFR < 90 mL/min/1.73 m2 [adjusted for age >40] [including results within 6 months of the screening visit, but including results within 12 months for patients with a 60 ≦ eGFR < 90 mL/min/1.73 m2])
- •Proteinuria that is equivalent to microalbuminuria or worse (Inclusion criteria: 2 or more cases of creatinine 30 mg/g in random urine at least 24 hours apart [including results within 6 months of the screening visit] or ≥30 mg of albuminuria in 24-hour urine)
- •For 24 hr urinary protein extraction (>4 mg/m2/hr) or for spot urinary protein/creatinine ratio (≥200 mg/g [Cr]) *Pediatrics: Aged <19 years
- •Abnormal left ventricular function as evidenced by MRI or echocardiography
- •Left ventricular mass index (LVMI)* >115 g/m2 (male), >95 g/m2 (female) or
- •Left ventricular wall thickness >12 mm (However, in the case of patients with hypertension, patients must have blood pressure treatment for at least 6 months prior to administration of the same drug) etc.
- •Clinically significant arrhythmias and conduction disturbances, etc.
- •Stroke or transient ischemic attack, etc., as evidenced by objective testing
- •Patients who have not previously received enzyme replacement therapy (ERT) or Chaperone therapy for treatment of Fabry disease
- •Patients who voluntarily consented and signed the informed consent form
- •Patients (female patients and partners of male patients who are of childbearing potential) who have agreed to use a medically appropriate method of contraception (intrauterine device, condoms, surgical methods such as vasectomy) during the clinical study
排除标准
- •Patients who participated in other studies in which investigational products are administered within 30 days prior to the screening visit
- •Patients with chronic kidney disease stage 4 to 5 (CKD 4-5; see Section 16.1)
- •Patients who are currently on dialysis or have a history of kidney transplantation, or patients scheduled for dialysis at the time of screening, or waitlisted for kidney transplantation
- •Patients who have started angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) treatment within 4 weeks prior to the screening visit or whose dose has been changed
- •Patients who are pregnant, breastfeeding, or planning to become pregnant or breastfeed during the clinical study
- •Patients with a history of HIV, hepatitis B/C or HIV antibodies, hepatitis B surface antigens, or hepatitis C antibodies
- •Patient whose medical, emotional, behavioral, or psychological conditions appear to interfere with compliance with the requirements of the clinical study according to the investigator's judgment
研究组 & 干预措施
Fabagal® (Agalsidase beta)
1 mg/kg, administered every 2 weeks for 12 months
干预措施: Fabagal® (Agalsidase beta) (Biological)
Active Comparator (Agalsidase beta)
1 mg/kg, administered every 2 weeks for 12 months
干预措施: Active comparator (Agalsidase beta) (Drug)
结局指标
主要结局
Evaluate the efficacy of Fabagal compared with active comparator (Agalsidase beta)
时间窗: Screening visit (Visit 0) and Visit 25 (Day 336)
The proportion of patients achieving a GL-3 score (score 0) in renal cells after treatment with Fabagal or Active comparator (Agalsidase beta) in patients with Fabry disease The proportion of patients achieving a GL-3 score (score 0) in renal cells after treatment with Fabagal or Active comparator (agalsidase beta) in patients with Fabry disease The primary endpoint is a comparison of the proportion of subjects in each group who achieve a score of Zero on the renal capillary endothelium histology. The score is graded on a scale from 0-3 (normal, mild, moderate, and severe). * 0: signified no visible inclusions * 1: signified multiple discrete lipid granules * 2: signified single or multiple aggregates of lipid granules * 3: signified aggregates of lipid granules either large enough or numerous enough to cause clear distortion of the luminal surface
次要结局
- Change from baseline in GL-3/lyso Gb-3 concentration in urine and blood after administration of 24 doses of Fabagal compared to active comparator(Screening visit (Visit 0), Visits 3, 5, 7, 9, and 11 (Days 28, 56, 84, 112, and 140), Visit 13 (Day 168), Visits 15, 17, 19, 21, and 23 (Days 196, 224, 252, 280, and 308) and Visit 25 (Day 336))
- Change from baseline in GL-3 levels in renal cells after administration of 24 doses of Fabagal compared to active comparator(Screening visit (Visit 0) and Visit 25 (Day 336))
- Change from baseline in renal function test values (estimated Glomerular Filtration Rate, eGFR) after administration(Screening visit (Visit 0), Visit 13 (Day 168), and Visit 25 (Day 336))
- Change from baseline in pain score after administration of 24 doses of Fabagal compared to active comparator (Short Form McGill Pain Questionnaire-2)(Visits 1, 13, and 25 (Days 0, 168, and 336))
- Change from baseline in quality of life after administration of 24 doses of Fabagal compared to active comparator (SF-36v2 questionnaire)(Visits 1, 13, and 25 (Days 0, 168, and 336))